Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Crescita Therapeutics Inc T.CTX

Alternate Symbol(s):  CRRTF

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.


TSX:CTX - Post by User

Bullboard Posts
Post by FrozenInOntarioon Jul 16, 2019 10:38am
86 Views
Post# 29924685

Extended patent protection for Pliagis

Extended patent protection for PliagisMajor news...   I might be wrong but seems to me that Pliagis coming off protection was holding the stock down or acting as a break in their ascent.   Despite this,  they got partners involved.   And now, we know why.   Thinking about it, one could have wonder why Taro did partner for a drug coming off patent when their line of business is doing generics and they could have copied them.

Anyway, this news is more than excellent and the stock has a lot of potential.   This could rerate a lot higher. 

And what the heck, can not hold myself while looking at the handle of another poster.  BINGOOOOOOOOOOOOOOOOOOO  !!!! We are off to the races...

GLTA
Bullboard Posts